United Therapeutics Corp. (UTHR)
562.02
-3.70
(-0.65%)
USD |
NASDAQ |
Nov 06, 16:00
566.66
+4.64
(+0.83%)
After-Hours: 20:00
United Therapeutics Net Income (TTM) : 1.231B for Sept. 30, 2026
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 1.231B |
| June 30, 2026 | 1.311B |
| March 31, 2026 | 1.287B |
| December 31, 2025 | 1.335B |
| September 30, 2025 | 1.272B |
| June 30, 2025 | 1.242B |
| March 31, 2025 | 1.211B |
| December 31, 2024 | 1.195B |
| September 30, 2024 | 1.111B |
| June 30, 2024 | 1.069B |
| March 31, 2024 | 1.050B |
| December 31, 2023 | 984.80M |
| September 30, 2023 | 899.80M |
| June 30, 2023 | 871.50M |
| March 31, 2023 | 728.30M |
| December 31, 2022 | 727.30M |
| September 30, 2022 | 707.40M |
| June 30, 2022 | 630.80M |
| March 31, 2022 | 687.40M |
| December 31, 2021 | 475.80M |
| September 30, 2021 | 462.40M |
| June 30, 2021 | 470.90M |
| March 31, 2021 | 405.40M |
| December 31, 2020 | 514.80M |
| September 30, 2020 | 468.60M |
| Date | Value |
|---|---|
| June 30, 2020 | 429.80M |
| March 31, 2020 | 527.80M |
| December 31, 2019 | -104.50M |
| September 30, 2019 | -91.80M |
| June 30, 2019 | -117.70M |
| March 31, 2019 | -149.90M |
| December 31, 2018 | 589.20M |
| September 30, 2018 | 542.90M |
| June 30, 2018 | 712.70M |
| March 31, 2018 | 483.80M |
| December 31, 2017 | 417.90M |
| September 30, 2017 | 509.20M |
| June 30, 2017 | 394.70M |
| March 31, 2017 | 656.80M |
| December 31, 2016 | 713.70M |
| September 30, 2016 | 708.04M |
| June 30, 2016 | 1.011B |
| March 31, 2016 | 903.78M |
| December 31, 2015 | 651.64M |
| September 30, 2015 | 662.93M |
| June 30, 2015 | 173.27M |
| March 31, 2015 | 185.91M |
| December 31, 2014 | 340.07M |
| September 30, 2014 | 193.82M |
| June 30, 2014 | 281.75M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (TTM) Benchmarks
| Liquidia Corp. | 138.61M |
| Alnylam Pharmaceuticals, Inc. | 2.724B |
| Exelixis, Inc. | 885.14M |
| Gilead Sciences, Inc. | -3.863B |
| Insmed, Inc. | -605.61M |